Worldwide

Press Releases

Soterix Medical Inc. receives FDA IDE for Clinical Trial on Use of High-Definition transcranial Direct Current Stimulation (HD-tDCS) to improve IQ in pediatric Down syndrome.

New York City – Oct 25, 2012

Aug 27, 2012 Soterix Medical Inc. receives FDA IDE for Clinical Trial on Use of High-Definition transcranial Direct Current Stimulation (HD-tDCS) to improve IQ in pediatric Down syndrome. This small pilot study of Soterix Medical Inc. exclusive High-Definition tDCS technology will be lead by investigators at University of Wisconsin-Madison under IRB approval. High-Definition tDCS is the only non-invasive, brain targeted, and low-intensity technology designed to promote neuroplasticity.

More about pediatric Down syndrome at NIH

For more on Soterix Medical HD-tDCS

More about Soterix Medical Inc. Limited Total Energy for Susceptible Populations

Media Contact
Narges Ghazi
Email: contact@soterixmedical.com

At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.

Latest Press Releases